Spyre Therapeutics(NASDAQ) SYRE

Spyre helps people with serious stomach and joint swelling by creating long-lasting medicines. Its products target common digestive issues like Crohn's disease and painful conditions like arthritis. These treatments aim to work longer so patients can take fewer shots over time.

What Is in the Pipeline?

• SPY001: A human antibody designed to block immune cells from entering the gut to treat inflammatory bowel disease; currently in Phase 2 clinical trials.
• SPY002 and SPY072: Two antibody candidates that block a protein called TL1A to reduce inflammation in the gut and joints; currently being tested for digestive and rheumatic diseases.
• SPY003: A treatment targeting a specific immune system messenger called IL-23; engineered with a longer half-life to stay in the body for extended periods.
• Combination Therapies: New medicines like SPY120 and SPY130 that mix two different antibodies into one treatment to improve how well they work for patients.

Recent Growth and Partnerships

• Acquired the assets of Pre-Merger Spyre in 2023 to focus entirely on its current portfolio of gut and joint treatments.
• Partnered with Paragon Therapeutics to license intellectual property for four research programs, including the core SPY001, SPY002, and SPY003 projects.
• Signed agreements with WuXi Biologics for manufacturing and development services to support its clinical trial drug supply.
• Hired its first Chief Commercial Officer in January 2026 to begin planning for future product sales and market entry.

Special Engineering Strengths

Spyre uses a technology called YTE substitutions to make its antibodies last longer in the human body. This specialized engineering aims to allow patients to receive treatments only twice a year rather than every few weeks.

The Financial Picture

• Revenue reached $90.5 million in Q4 2025, compared to zero revenue in the previous year.
• Operating income was -$57.2 million in Q4 2025, an improvement of 6.7% from the previous year.
• Net income fell to -$62.5 million in Q4 2025, down 11.1% from the year-ago period.
• Market capitalization grew to $11.3 billion in Q4 2025, up 935.5% year-over-year.

Bottom Line

Spyre has transitioned from an early research firm into a clinical-stage company with multiple treatments in human testing. By focusing on long-acting and combination therapies, it is building a specialized business around the growing need for more convenient immune-mediated disease treatments.